Abstract
Background Kidney transplant recipients (KTRs) were given a 3-dose primary series of COVID-19 vaccination as they were vulnerable to infection due to immunosuppression.
Methods This study was a longitudinal evaluation of nAB dynamics in 43 KTRs in a low-middle income setting receiving 3-dose homologous (mRNA-1273- mRNA-1273- BNT162b2) vaccination against COVID-19. Samples were obtained at time-points (TP) 0- pre-vaccination, TP1- 1 month post first dose(mRNA-1273), TP2-1-month post second dose (mRNA-1273), TP3- 4 months post-second dose, TP4- 2 weeks post-third dose(BNT162b2), TP5-5 months post-third dose and TP6-12 months-post third dose. Anti-SARS-CoV-2 nAB were detected using Genscript cPassTM pseudoviral neutralization kit. Demographic and clinical details were obtained through interviewer administered questionnaires.
Results Pre-vaccination serum analysis showed n=7 KTRs had prior COVID-19 infection, classified as ‘infected+vaccinated,’ while others were ‘vaccinated. ‘ Both groups were similar in age(41.7years vs 46.7years,p=0.2383), gender, and transplant characteristics. Seroconversion and MAB in the vaccinated and infected+vaccinated KTRs were:TP1-8.3% vs 100%(p<0.001), MAB-64.3IU/ml vs 1424IU/ml(p=0.0167TP2-52.7% vs 100%(p=0.0194), MAB-175IU/ml vs 2790IU/ml(p<0.0001), TP3-100% vs 100%, MAB-106IU/ml vs 2153IU/ml(p=0.0002), TP4-100% vs 100%, MAB-736 IU/ml vs 2152IU/ml(p=0.0307) and TP6-100% vs 100%, MAB >2565IU/ml vs >3028IU/ml(p=0.5238) No factors were associated with seroconversion or MAB.
Conclusion KTRs receiving a three-dose mRNA COVID-19 vaccine regime maintained strong nAB levels at one-year follow-up, with comparable antibody levels seen between KTRs with prior infection + vaccination and vaccination alone.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed written consent was obtained from the participants. Ethics approval was obtained from the Ethics Review Committee, Faculty of Medicine, University of Peradeniya (2021/EC/14). All methods were performed in accordance with the relevant guidelines and regulations.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
